The Perlmutters are long-time supporters of the medical center’s cancer programs.
New York University’s have recently announced that they have been recipients or a gift of more $50 million, partly from Laura and Isaac Perlmutter personally as well as from the Laura and Isaac Perlmutter Foundation Inc, which will be used by the center to advance cancer research and treatment.
In recognition of the Perlmutters’ ongoing support, New York University has taken the step of renaming the Langone center, which is designated as a National Cancer Institute. The center will now be known as the Laura and Isaac Perlmutter Cancer Center at NYU Langone.
Announcing details of the Perlmutter’s generous endowment and the decision to remame the center in their honor, Robert I. Grossman, MD, the current dean and CEO OF NYU Langone stated that for the past three decades Laurie and Ike have been a constant source of support for our programs, and always in a manner of generosity and foresight. Thank’s to their most recent gift the Medical Center’s already world-class cancer care, research, and education programs to become truly integrated across all disciplines, regardless of their physical locations within our growing care network.
Their gift ensures that all facilities embraced by the new Perlmutter Cancer Center will have a dynamic infrastructure in place to strengthen the bridges between our scientists and clinicians. “The naming of the Perlmutter Cancer Center is a tribute to our Super Hero supporters for their tireless efforts on behalf of our institution.” Dr Grossman summed up.
The Perlmutters’ most recent gift, will enable even greater program coordination, foster new synergies, and unite cancer research, patient care, and education around the singular focus of producing better outcomes for patients, as well as providing the Perlmutter Cancer Center with the facilities to attract and retain the services of nationally recognized physicians and research scientists.
In addition the Center will be given more tools to enhance progress in cancer research, diagnosis and treatment, as well as the education of the next generation of clinical and scientific leaders at NYU School of Medicine.
Dafna Bar-Sagi, PhD, senior vice president and vice dean for science, as well as chief scientific officer at NYU School of Medicine echoed Dr, Grossman’s remarks by adding that the medical profession is now at a moment in history when there are great opportunities to make bold advances in cancer research.
“ At the same time, , the research community as a whole is facing extreme challenges, with having to contend with plunging national research budget cuts. “ As a result of the Perlmutter’s generosity the center will be able to continue focusing on the prevention and treatment of cancer and realize the full potential of the extraordinary research that goes on at NYU Langone.” Dr. Bar Sagi explained.
Mrs. Laura Perlmutter has been a member of the NYU Langone community for more than 30 years, initially as a volunteer in the hospital’s gift shop, later rising to become president of the Tisch Hospital Auxiliary, a position she held for seven years, from 1985 to 1992, as well as sitting on the board of trustees for NYU Langone from the same year. Laura Perlmutter has sat on the Cancer Advisory Board since 2005.
Isaac Perlmutter was also recently seconded on to the board of trustees for the NYU Langone Cancer Center.
Isaac “Ike” Perlmutter was born in Mandatory Palestine. After serving in the Israeli army during the Six-Day War of 1967, Perlmutter emigrated to the United States, settling in New York, where, through a combination of hard work, determination, and innate business skills which characterized him throughout his working life, either established or acquired a number of business ventures. Among the companies that Isaac Perlmutter has owned are Remington Products and Marvel Toys, while today Perlmutter acts as CEO of Marvel Entertainment, a position he has held since January 2005, remaining with the company after it was fully acquired by The Walt Disney Company on the end of December 2009.